Clinical trial
A Prospective, Multicenter, Single-arm Objective Performance Criteria Evaluation of the Safety and Efficacy of a Novel SeaLA™ Left Atrial Appendage Occluder in Patients With Nonvalvular Paroxysmal Atrial Fibrillation
NCT05911685 is registered in ClinicalTrials.gov with Hangzhou Dinova EP Technology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Single-arm Objective Performance Criteria Evaluation of the Safety and Efficacy of a Novel SeaLA™ Left Atrial Appendage Occluder in Patients With Nonvalvular Paroxysmal Atrial Fibrillation
- Lead sponsor
- Hangzhou Dinova EP Technology Co., Ltd
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- March 26, 2019
- Completion date
- January 21, 2025
- Enrollment
- 163 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.